about
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cellsRole of ADAMs in cancer formation and progression.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Mammaglobin a in breast cancer: existence of multiple molecular forms.Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells.The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?Investigation of the molecular profile of basal cell carcinoma using whole genome microarraysSurvivin: a promising tumor biomarker.EGFR and HER-2 antagonists in breast cancer.Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesDrug resistance in cancer - searching for mechanisms, markers and therapeutic agents.Identification of pancreatic cancer invasion-related proteins by proteomic analysisComparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesNeratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.Alterations in integrin expression modulates invasion of pancreatic cancer cells.The role of ADAMs in disease pathophysiology.Survivin: a new target for anti-cancer therapy.BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcomeUse of molecular markers for predicting therapy response in cancer patients.The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.EGFR and HER2 inhibition in pancreatic cancer.Structure--activity relationship and mode of action of N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters: novel organometallic anticancer compounds.2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agents.Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.Caspase 3 in breast cancer.Use of a panel of novel genes for differentiating breast cancer from non-breast tissues.Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes.Mammaglobin a: a promising marker for breast cancerHER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
P50
Q21093314-EA19C1FF-3322-4DAF-B074-75996CE56F96Q33410732-4FA0A0FE-4E45-45D0-90F8-212B3ED19744Q34363419-4D8363C9-166D-4089-90D1-7F03D1C6F35BQ34378071-DE0BC493-4F27-4E04-8D3B-4031EEC3626AQ34850820-4B7ACC7B-3BB6-4097-A9F8-44B68AD53DF8Q35206311-A5049C52-87BB-47ED-93ED-0C6CCD66CB85Q35589231-ED78427F-D81A-45B3-A8D4-A7043FAEF876Q36726840-F2328E82-B378-4613-8B9F-201A211DA037Q36861342-8CD3A410-AE63-48C1-9C58-25A7DBE4C50AQ36940730-6E2DAB6C-F861-4BD6-BEA7-4BFB62220E0BQ37008882-DE34599A-D516-4CE2-B91C-6090EB9CA35BQ37107126-34EB1865-9899-43F8-ABCE-D3DD7FF847BFQ37269217-26CAA70B-C6E2-4B07-9AF0-EE8D436A0BF6Q37381579-80191CE0-BB1D-4E9C-BB91-D573262D2B42Q37395543-79D6D5D3-DADB-4194-BF99-B65FF5B863AFQ37466475-80A26062-FB31-435B-8464-1A44332F8063Q37533048-9C049953-CA8A-452C-9709-0E559CEB8A0FQ37689788-D11BEE25-DD6B-4217-8401-F96673F55605Q37777760-76611D3B-96BD-4033-90B7-4BC838D86F1BQ39205999-FC572CE5-9CC9-4C47-823C-755246EA1007Q39250672-4C9956AE-53A9-42EF-8932-05DF27529E8CQ39257360-26A3F2FB-A61D-4091-B0EB-5D414DBC23DCQ39355731-FCB40613-BBCD-4DCD-98A7-7CDC87A8CEB8Q39607566-3C2467E0-3FC0-435A-A501-E3683EB75D68Q39672435-80970D4C-E4C5-4349-8E35-A981B6F9E127Q39700483-426E96CE-D385-40FA-BD1A-E46DEE5411B2Q39727725-EA453D84-C72E-4261-BAEF-C917C1993A70Q44308431-5726FFAA-53B9-46DD-AAFB-55D1C976E678Q46769858-6E53AD1E-C8E0-49DC-9E9A-FB095A32E8A1Q54654768-1F5482B8-D605-418E-9793-F0DC1092BFFEQ60194267-5827ACDE-039F-40BA-8CAE-7F639F3DBAADQ90655751-6B142B28-2DD1-433A-B8AD-097F2E8D886C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Norma O'Donovan
@ast
Norma O'Donovan
@en
Norma O'Donovan
@es
Norma O'Donovan
@nl
Norma O'Donovan
@sl
type
label
Norma O'Donovan
@ast
Norma O'Donovan
@en
Norma O'Donovan
@es
Norma O'Donovan
@nl
Norma O'Donovan
@sl
prefLabel
Norma O'Donovan
@ast
Norma O'Donovan
@en
Norma O'Donovan
@es
Norma O'Donovan
@nl
Norma O'Donovan
@sl
P106
P21
P31
P496
0000-0003-1113-3872